Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Http://affyxell.com/bbs/?so_table=news_en&mode=VIEW&num=18&category=&findType=&findWord=&sort1=&sort2=&page=1
AffyXell Therapeutics Co., Ltd. presented the results of the Efficacy PoC evaluation of AFX001, a genetically engineered MSC under development for acute graft-versus-host disease (aGVHD), at the International Society for Cell Therapy (ISCT 2023) held in Paris, France.
AFX001 is an MSC therapeutic designed to secreted Affimer® molecules targeting CD40L based on AffyXell’s platform technology.
AffyXell confirmed the clinical score improvement through the xenograft GVHD model, and explained that the treatment effect of GVHD can be expected by suppressing the activity of T cells and B cells.
Currently, AffyXell Therapeutics Co., Ltd. is conducting non-clinical trials for IND submission of AFX001 for aGVHD.
Https://medicalxpress.com/news/2023-05-rapid-diagnostic-multiple-resistance-important.html
https://kabla-mx.translate.goog/pruebasrapidas/resist5-oknvi-carbapenemasas-coris/?_x_tr_sl=es&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
https://bestbion.com/wp-content/uploads/2022/01/bestbiondx-carbapenemasen-resist-bc-rescape.pdf
The U.K. IVD market reached $4.6 billion in 2022, according to an estimate by Kalorama Information, a sister brand of LabPulse, in its 30-Country IVD Market Atlas.
The U.K. market is expected to grow just under 3% per year for the next five years, the report said, faster than Italy, France, or the Netherlands, and at about the same rate as Germany.
https://www.labpulse.com/business-insights/article/15446997/uk-ivd-market-grows-to-46-billion-brexit-not-a-factor
We have just tapped into a multi billion pound IVD Market and Launch D are about to go into Germany one of the biggest markets in Europe
https://www.globenewswire.com/en/news-release/2022/12/19/2576026/0/en/In-Vitro-Diagnostics-IVD-Market-Size-Share-to-Surpass-141-16-Billion-by-2028-Vantage-Market-Research.html
Sensitivity & Specificity excellent Results .....
https://www.corisbio.com/pdf/Products/Coris-RESIST-D-CUS-10-RR-02-2023-03-V1.pdf
Very clever purchase IMHO
https://www.dzif.de/en/rapid-diagnostic-test-detect-multiple-resistance-determinants-against-important-carbapenem
Sorry if iv'e missed this can't seem to find any info re Avacta Affyxell presenting ?
Data will be presented at International Society for Cell & Gene Therapy, May 2023 (AffyXell and Avacta) https://www.isctglobal.org/isct2023/home